The rise of AI in health care presents new challenges related to the patentability and regulation of AI-driven medical ...

Patent Approval Reinforces Nexalin’s Leadership in Non-Invasive Brain Stimulation for Addiction TreatmentHOUSTON, TX, April ...

Patent eligibility under 35 U.S.C. § 101 remains one of the most hotly contested and unpredictable areas of U.S. patent law.

Nexalin Technology receives US patent for Deep Intracranial Frequency Stimulation technology in treating substance use disorders: Houston, Texas Wednesday, April 16, 2025, 17:00 H ...

In 2024, the USPTO published guidance on whether an AI-based invention is patent eligible. The guidance includes three hypothetical ...

The allowed claims in this patent encompass core methods and compositions ... designed to address the long-standing challenges of applying CAR-T therapies to solid tumors, positioning the program ...